A detailed history of Price T Rowe Associates Inc transactions in Medicinova Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 20,700 shares of MNOV stock, worth $31,671. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,700
Previous 20,700 -0.0%
Holding current value
$31,671
Previous $31,000 3.23%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$2.1 - $2.6 $47,040 - $58,240
-22,400 Reduced 51.97%
20,700 $45,000
Q1 2022

May 16, 2022

BUY
$2.19 - $2.81 $25,404 - $32,596
11,600 Added 36.83%
43,100 $115,000
Q2 2021

Aug 16, 2021

SELL
$3.76 - $5.14 $11,607 - $15,867
-3,087 Reduced 8.93%
31,500 $134,000
Q1 2021

May 17, 2021

BUY
$4.81 - $8.74 $166,363 - $302,290
34,587 New
34,587 $175,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $75M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.